GlassScriptPhysician profile
Joshua Kalish
NPI 1134757347
$2,366.75
in general payments reported to CMS, 2019-2025
13 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.67 · 2023: $287 · 2024: $829 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,097.09 | 2021-2025 | Clareon, Clareon Panoptix Pro, Centurion |
| Johnson & Johnson Surgical Vision, INC. | $366.71 | 2024-2025 | Tecnis Iol, Veritas Vision System, Tecnis Simplicity |
| Abbvie INC. | $265.25 | 2024-2025 | |
| Harrow Eye, LLC | $123.90 | 2024 | Iheezo, Flarex, Verkazia |
| Bausch & Lomb Americas INC. | $104.52 | 2025 | Ic-8 Apthera Iol |
| Sun Pharmaceutical Industries INC. | $91.61 | 2025 | |
| New World Medical,INC. | $89.99 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Tarsus Pharmaceuticals, INC. | $72.18 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $38.65 | 2025 | Iyuzeh |
| Genentech USA, INC. | $31.02 | 2025 | Vabysmo |
| Glaukos Corporation | $30.25 | 2024-2025 | Radius, Idosetr |
| Rxsight INC | $28.96 | 2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $26.62 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Kalish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.